Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmstandard

Full company profile

uuid0037kiz

Namestring
Pharmstandard
Legal namestring
JSC Pharmstandard
Websiteurl
pharmstd.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Pharmstandard is a Russian pharmaceutical manufacturer and commercialization platform headquartered in Dolgoprudny, Moscow Region. According to the company, it operates one of the largest domestic pharmaceutical manufacturing footprints in Russia, with consolidated capacity exceeding 1.7 billion packs of finished pharmaceutical products and over 700,000 litres of pharmaceutical substances annually across multiple GMP-certified, state-of-the-art production facilities compliant with EAEU GDP rules. Its portfolio spans over 400 pharmaceutical products across 30 dosage forms, including more than 140 medicines on Russia's Vital and Essential Drugs (VED) list, serving therapeutic areas such as diabetes, cardiovascular disease, gastroenterology, neurology, oncology, infectious diseases (tuberculosis, HIV, hepatitis, COVID), and orphan/autoimmune indications.

The company's business model rests on two reinforcing pillars: (1) proprietary manufacture and sale of branded and generic Rx/OTC pharmaceuticals to healthcare professionals, patients, and government procurement channels within Russia; and (2) a Business Development platform that provides end-to-end commercialization services to international pharmaceutical partners — including registration, pre-launch and launch support, marketing and sales, market access, distribution, patient navigation, medical services, knowledge management systems, digital healthcare management, localization (secondary packaging / FDF), serialization, and pharmacovigilance. The company maintains long-term GTM partnerships with over 15 major multinational pharmaceutical companies, including AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ferring, Roche, Gilead, Johnson, LifeScan, Merck, Novartis, Pfizer, Takeda, and Zentiva.

Its go-to-market is sales-led and enterprise-oriented, distributing through B2B pharma partnerships, direct government healthcare procurement for essential medicines, and retail pharmacy networks for OTC products, all within Russia. The company was founded in 2003 (with the corporate copyright notice referencing 2007) and previously traded on MOEX under PHST.RTS before being delisted; it reports 5,001–10,000 employees and is led by Viktor Kharitonin as Executive Director and Grigory Potapov as CEO. In June 2026 it signed an investment agreement at SPIEF-26 to construct a large-scale live vaccine production complex in the Technopolis special economic zone (Moscow region), in partnership with the Moscow city government, extending its footprint from small-molecule generics into biologics/vaccines.

Short descriptiontext

Pharmstandard is a Russian pharmaceutical manufacturer operating one of the country's largest GMP-certified production footprints, supplying over 400 products across 30 dosage forms (140+ on the VED list) and providing end-to-end commercialization, distribution, and localization services to domestic healthcare channels and multinational pharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersMoscow, Russia
HQ citystring
Moscow
HQ countrystring
Russia
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, prescription drugs, GMP-certified production, vital essential drugs, contract pharmaceutical services
Industry4 codes
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeHardware Sales
Description

Pharmstandard generates revenue primarily through the manufacture and sale of pharmaceutical products, including both prescription (Rx) and over-the-counter (OTC) drugs. The company produces over 400 pharmaceutical products across 30 dosage forms, with over 140 medicines included in Russia's Vital and Essential Drugs List (VED).

pharmstd.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pharmstandard develops and manufactures a broad portfolio of over 400 pharmaceutical products across 30 dosage forms, including over 140 medicines on Russia's Vital and Essential Drugs List, spanning therapeutic areas such as diabetes, cardiovascular, oncology, infectious diseases, and autoimmune disorders. The company operates GMP-certified state-of-the-art manufacturing facilities capable of producing over 1.7 billion packs of finished dosage forms and 700,000 litres of pharmaceutical substances annually. It also provides end-to-end partnership services to multinational pharmaceutical companies covering registration, marketing & sales, market access, distribution, serialization, localization, and pharmacovigilance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Manufacturing capacity of over 1.7 billion packs per year and over 700,000 litres of pharmaceutical substances
+2 more records
Product overview1 text field

Pharmstandard is Russia's leading pharmaceutical company operating as a single unified pharmaceutical manufacturing and commercialization platform. The portfolio consists of over 400 pharmaceutical products across 30 dosage forms, including 140+ Vital and Essential Drugs List medicines, supported by GMP-certified manufacturing capacity exceeding 1.7 billion packs and 700,000 litres of substances annually. The company provides integrated business development services encompassing registration, marketing, distribution, pharmacovigilance, and localization support for partner pharmaceutical companies.

Product and service3 records
1Pharmaceutical Products Portfolio
CategoryPharmaceutical products
2GMP-certified Manufacturing Services
CategoryPharmaceutical manufacturing services
3Business Development and Partnership Services
CategoryPharmaceutical commercialization and partnership services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
1Moscow Government (City of Moscow)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-15
thepharmaletter.com
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
6Eisai LLC
Strategic tierCoreTypeGTM or Marketing Partner
bd.pharmstd.com
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Strategic tierCoreTypeGTM or Marketing Partner
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

European generics and consumer healthcare company with established CIS and Russian distribution. Comparable as a multinational generics-and-OTC player operating in the same Russian retail, hospital, and government procurement channels as Pharmstandard.

TypeDirect peer
Description

Major Russian pharmaceutical manufacturer with a broad generics and Rx portfolio across multiple therapeutic areas. Directly comparable in scale, domestic manufacturing focus, and reliance on the Russian institutional and retail pharmacy channels.

TypeDirect peer
Description

Russian pharmaceutical manufacturer specializing in endocrinology, neurology, and biotech products including insulins. Comparable as a domestic manufacturer with a strong VED-aligned portfolio and government procurement orientation.

TypeBroad incumbent
Description

Hungarian-headquartered pharmaceutical company with a significant Russian footprint through Gedeon Richter-RUS. Comparable as a multinational manufacturer with established Russian manufacturing and a broad Rx portfolio overlapping Pharmstandard's therapeutic areas.

TypeDirect peer
Description

Russian pharmaceutical company with branded Rx and OTC products across multiple therapeutic categories. Directly comparable in product mix, retail and hospital channel coverage, and the breadth-vs-depth portfolio strategy.

TypeDirect peer
Description

Russian biotech company developing and manufacturing biological products including biosimilars and innovative biologics. Comparable to Pharmstandard's biologics expansion ambitions and its push into higher-value specialty therapeutics in Russia.

TypeDirect peer
Description

One of Russia's largest domestic pharmaceutical manufacturers with a broad Rx and hospital portfolio and contract manufacturing capabilities. Directly comparable to Pharmstandard as a top-tier Russian pharma with diversified dosage forms and government procurement exposure.

8Polysan
TypeDirect peer
Description

Russian pharmaceutical manufacturer with a portfolio in cardiology, neurology, infectious diseases, and hospital injectables. Comparable as a domestic multi-therapeutic manufacturer competing in the same VED and government procurement channels.

TypeBroad incumbent
Description

Slovenian-headquartered generic and specialty pharmaceutical manufacturer with strong presence in Russia and CIS. Comparable as a large-scale European generics/specialty manufacturer that competes with Pharmstandard in the Russian generics and VED market.

TypeDirect peer
Description

Russian pharmaceutical company focused on OTC and consumer health products with strong retail pharmacy distribution. Comparable to Pharmstandard's OTC channel and the retail pharmacy distribution leg of its business.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment14 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmstandard

Pharmaceutical Manufacturingpharmstd.com

Pharmstandard is a Russian pharmaceutical manufacturer operating one of the country's largest GMP-certified production footprints, supplying over 400 products across 30 dosage forms (140+ on the VED list) and providing end-to-end commercialization, distribution, and localization services to domestic healthcare channels and multinational pharma partners.

What Pharmstandard does

Pharmstandard is a Russian pharmaceutical manufacturer and commercialization platform headquartered in Dolgoprudny, Moscow Region. According to the company, it operates one of the largest domestic pharmaceutical manufacturing footprints in Russia, with consolidated capacity exceeding 1.7 billion packs of finished pharmaceutical products and over 700,000 litres of pharmaceutical substances annually across multiple GMP-certified, state-of-the-art production facilities compliant with EAEU GDP rules. Its portfolio spans over 400 pharmaceutical products across 30 dosage forms, including more than 140 medicines on Russia's Vital and Essential Drugs (VED) list, serving therapeutic areas such as diabetes, cardiovascular disease, gastroenterology, neurology, oncology, infectious diseases (tuberculosis, HIV, hepatitis, COVID), and orphan/autoimmune indications.

The company's business model rests on two reinforcing pillars: (1) proprietary manufacture and sale of branded and generic Rx/OTC pharmaceuticals to healthcare professionals, patients, and government procurement channels within Russia; and (2) a Business Development platform that provides end-to-end commercialization services to international pharmaceutical partners — including registration, pre-launch and launch support, marketing and sales, market access, distribution, patient navigation, medical services, knowledge management systems, digital healthcare management, localization (secondary packaging / FDF), serialization, and pharmacovigilance. The company maintains long-term GTM partnerships with over 15 major multinational pharmaceutical companies, including AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ferring, Roche, Gilead, Johnson, LifeScan, Merck, Novartis, Pfizer, Takeda, and Zentiva.

Its go-to-market is sales-led and enterprise-oriented, distributing through B2B pharma partnerships, direct government healthcare procurement for essential medicines, and retail pharmacy networks for OTC products, all within Russia. The company was founded in 2003 (with the corporate copyright notice referencing 2007) and previously traded on MOEX under PHST.RTS before being delisted; it reports 5,001–10,000 employees and is led by Viktor Kharitonin as Executive Director and Grigory Potapov as CEO. In June 2026 it signed an investment agreement at SPIEF-26 to construct a large-scale live vaccine production complex in the Technopolis special economic zone (Moscow region), in partnership with the Moscow city government, extending its footprint from small-molecule generics into biologics/vaccines.

Pharmstandard firmographics

Firmographics
Name
Pharmstandard
Legal name
JSC Pharmstandard
Website
https://pharmstd.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Pharmstandard is a Russian pharmaceutical manufacturer operating one of the country's largest GMP-certified production footprints, supplying over 400 products across 30 dosage forms (140+ on the VED list) and providing end-to-end commercialization, distribution, and localization services to domestic healthcare channels and multinational pharma partners.
Ownership category
akta.pro rank

Pharmstandard industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAF
Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAGAMAD
Specialty Pharma & Biologics Distribution (GDP-compliant)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Supply Chain, Logistics & Cold Chain for Life Sciences

Keywords

  • Pharmaceutical manufacturing
  • Prescription drugs
  • GMP-certified production
  • Vital essential drugs
  • Contract pharmaceutical services

Where Pharmstandard is headquartered

Location

Headquarters

HQ city
Moscow
HQ country
Russia
HQ region
Europe

Offices2 records

Markets served

Pharmstandard business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pharmstandard generates revenue primarily through the manufacture and sale of pharmaceutical products, including both prescription (Rx) and over-the-counter (OTC) drugs. The company produces over 400 pharmaceutical products across 30 dosage forms, with over 140 medicines included in Russia's Vital and Essential Drugs List (VED).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Pharmstandard product offering

Product offering

Core offering

Pharmstandard develops and manufactures a broad portfolio of over 400 pharmaceutical products across 30 dosage forms, including over 140 medicines on Russia's Vital and Essential Drugs List, spanning therapeutic areas such as diabetes, cardiovascular, oncology, infectious diseases, and autoimmune disorders. The company operates GMP-certified state-of-the-art manufacturing facilities capable of producing over 1.7 billion packs of finished dosage forms and 700,000 litres of pharmaceutical substances annually. It also provides end-to-end partnership services to multinational pharmaceutical companies covering registration, marketing & sales, market access, distribution, serialization, localization, and pharmacovigilance.

Product overview

Pharmstandard is Russia's leading pharmaceutical company operating as a single unified pharmaceutical manufacturing and commercialization platform. The portfolio consists of over 400 pharmaceutical products across 30 dosage forms, including 140+ Vital and Essential Drugs List medicines, supported by GMP-certified manufacturing capacity exceeding 1.7 billion packs and 700,000 litres of substances annually. The company provides integrated business development services encompassing registration, marketing, distribution, pharmacovigilance, and localization support for partner pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Products Portfolio
  • GMP-certified Manufacturing Services
  • Business Development and Partnership Services

Quantifiable outcome

  • Manufacturing capacity of over 1.7 billion packs per year and over 700,000 litres of pharmaceutical substances
  • +2 more outcomes

Companies that use Pharmstandard

Customer profile

Segments3 records

Ideal customer profiles3 records

Pharmstandard technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Pharmstandard partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Pharmstandard competitors and assessment

Company assessment

Broad incumbents

  • Stada Arzneimittel: European generics and consumer healthcare company with established CIS and Russian distribution. Comparable as a multinational generics-and-OTC player operating in the same Russian retail, hospital, and government procurement channels as Pharmstandard.
  • Gedeon Richter: Hungarian-headquartered pharmaceutical company with a significant Russian footprint through Gedeon Richter-RUS. Comparable as a multinational manufacturer with established Russian manufacturing and a broad Rx portfolio overlapping Pharmstandard's therapeutic areas.
  • KRKA: Slovenian-headquartered generic and specialty pharmaceutical manufacturer with strong presence in Russia and CIS. Comparable as a large-scale European generics/specialty manufacturer that competes with Pharmstandard in the Russian generics and VED market.

Direct peers

  • Vertex (Verteks): Major Russian pharmaceutical manufacturer with a broad generics and Rx portfolio across multiple therapeutic areas. Directly comparable in scale, domestic manufacturing focus, and reliance on the Russian institutional and retail pharmacy channels.
  • Geropharm: Russian pharmaceutical manufacturer specializing in endocrinology, neurology, and biotech products including insulins. Comparable as a domestic manufacturer with a strong VED-aligned portfolio and government procurement orientation.
  • Valenta Pharm: Russian pharmaceutical company with branded Rx and OTC products across multiple therapeutic categories. Directly comparable in product mix, retail and hospital channel coverage, and the breadth-vs-depth portfolio strategy.
  • BIOCAD: Russian biotech company developing and manufacturing biological products including biosimilars and innovative biologics. Comparable to Pharmstandard's biologics expansion ambitions and its push into higher-value specialty therapeutics in Russia.
  • R-Pharm: One of Russia's largest domestic pharmaceutical manufacturers with a broad Rx and hospital portfolio and contract manufacturing capabilities. Directly comparable to Pharmstandard as a top-tier Russian pharma with diversified dosage forms and government procurement exposure.
  • Polysan: Russian pharmaceutical manufacturer with a portfolio in cardiology, neurology, infectious diseases, and hospital injectables. Comparable as a domestic multi-therapeutic manufacturer competing in the same VED and government procurement channels.
  • OTCPharm: Russian pharmaceutical company focused on OTC and consumer health products with strong retail pharmacy distribution. Comparable to Pharmstandard's OTC channel and the retail pharmacy distribution leg of its business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pharmstandard financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmstandard leadership team

Management profile

Number of profiles

Profiles3 records

Pharmstandard subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pharmstandard funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmstandard M&A and investment

M&A and investment

M&A1 record

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmstandard

What does Pharmstandard do?

Pharmstandard develops and manufactures a broad portfolio of over 400 pharmaceutical products across 30 dosage forms, including over 140 medicines on Russia's Vital and Essential Drugs List, spanning therapeutic areas such as diabetes, cardiovascular, oncology, infectious diseases, and autoimmune disorders. The company operates GMP-certified state-of-the-art manufacturing facilities capable of producing over 1.7 billion packs of finished dosage forms and 700,000 litres of pharmaceutical substances annually. It also provides end-to-end partnership services to multinational pharmaceutical companies covering registration, marketing & sales, market access, distribution, serialization, localization, and pharmacovigilance.

Is Pharmstandard a public or private company?

Pharmstandard is a private company. It is classified as unknown and is currently operating.

When was Pharmstandard founded?

Pharmstandard was founded in 2007. It employs 5,001 to 10,000 people.

Where is Pharmstandard based?

Pharmstandard is headquartered in Moscow, Russia, in the Europe region.

How does Pharmstandard make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Pharmstandard's main competitors?

Broad incumbents on record are Stada Arzneimittel, Gedeon Richter and KRKA. Direct peers are Vertex (Verteks), Geropharm, Valenta Pharm, BIOCAD, R-Pharm, Polysan and OTCPharm.

Does Pharmstandard have an API?

No public API is recorded for Pharmstandard.

What industry is Pharmstandard in?

Pharmstandard's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals